1-9 of 9
Pauline Funchain
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3210: Neoadjuvant-adjuvant pembrolizumab (PEMBRO) in advanced basal cell carcinoma (BCC) induces memory-like T cell expansion with therapeutic promise

Free
Yee Peng Phoon, Beatriz Coutinho de Oliveira, Grace Jones, James M. Isaacs, Jennifer Ko, Lucy B. Kennedy, Pauline Funchain, Thach-Giao Truong, Brian Gastman, Jan J. Melenhorst
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3210.
https://doi.org/10.1158/1538-7445.AM2025-3210
Published: 21 April 2025
View articletitled, Abstract 3210: Neoadjuvant-adjuvant pembrolizumab (PEMBRO) in advanced basal cell carcinoma (BCC) induces memory-like T cell expansion with therapeutic promise
Journal Articles

Abstract 3393: A pan-cancer analysis of cancer-predisposition germline pathogenic variants (gPVs) utilizing the cancer genome atlas (TCGA) reveals distinct survival trends associated with immune response pathways

Free
Alan Shen, Lin Li, Joshua Arbesman, Ying Ni, Pauline Funchain
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3393.
https://doi.org/10.1158/1538-7445.AM2025-3393
Published: 21 April 2025
View articletitled, Abstract 3393: A pan-cancer analysis of cancer-predisposition germline pathogenic variants (gPVs) utilizing the cancer genome atlas (TCGA) reveals distinct survival trends associated with immune response pathways
Journal Articles

Abstract CT261: Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness

Free
James Isaacs, Tamara A. Sussman, Lucy B. Kennedy, Joshua Arbesman, Brian Gastman, Millennia Zhou, Emily Zabor, Claudia Diaz-Montero, Jennifer Ko, Pauline Funchain
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): CT261.
https://doi.org/10.1158/1538-7445.AM2024-CT261
Published: 05 April 2024
View articletitled, Abstract CT261: Phase II trial of nivolumab in combination with talazoparib in patients with unresectable or metastatic melanoma and mutations in BRCA or BRCA-ness
Journal Articles

Abstract 7518: Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial

Free
Grace M. Jones, James Isaacs, Lucy Boyce Kennedy, Jennifer Ko, Allison Vidimos, Alok Vij, Christine Poblete-Lopez, Jennifer Lucas, Yee Peng Phoon, Melissa McEnery-Stonelake, Jon Meine, Thach-Giao Truong, Pauline Funchain, Brian Gastman
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7518.
https://doi.org/10.1158/1538-7445.AM2024-7518
Published: 22 March 2024
View articletitled, Abstract 7518: Neoadjuvant-adjuvant pembrolizumab in resectable advanced basal cell carcinoma of the head and neck: An open-label, single-arm, phase 1b trial
Journal Articles

Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics

Free
Yee Peng Phoon, Jared E. Lopes, Lukas W. Pfannenstiel, C. Marcela Diaz-Montero, Ye F. Tian, Marc S. Ernstoff, Pauline Funchain, XiaoXia Li, Heather C. Losey, Raymond J. Winquist, Brian R. Gastman
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 1818.
https://doi.org/10.1158/1538-7445.AM2023-1818
Published: 04 April 2023
View articletitled, Abstract 1818: Developing an autologous humanized mouse model to assess responses to novel immunotherapeutics
Journal Articles

Abstract 5963: Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment

Free
Alan Shen, Roshan Lodha, Brandon Bungo, Michelle Arbesman, Nikhil Pramod, Jennifer Ko, Brian Gastman, C. Marcela Diaz, Timothy Chan, Joshua Arbesman, Pauline Funchain
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 5963.
https://doi.org/10.1158/1538-7445.AM2023-5963
Published: 04 April 2023
View articletitled, Abstract 5963: Germline variant positive melanoma patients exhibit an enhanced inflammatory microenvironment
Journal Articles

Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma

Free
Benjamin Switzer, Manu R. Pandey, Alexandra Valentine, Agnieszka Witkiewicz, Erik Knudsen, Kristopher Attwood, Joseph Tario, Pauline Funchain, Joseph J. Drabick, Hemn Mohammadpour, Marc S. Ernstoff, Igor Puzanov, Elizabeth A. Repasky, Shipra Gandhi
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): CT568.
https://doi.org/10.1158/1538-7445.AM2022-CT568
Published: 15 June 2022
View articletitled, Abstract CT568: β-2 adrenergic receptor (AR): Another immune checkpoint (IC)" A phase II clinical trial of propranolol (P) with pembrolizumab (Pem) in patients with unresectable stage III and stage IV melanoma
Journal Articles

Abstract 4087: Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma

Free
Gurkan Bebek, Kristi L. Bennett, Pauline Funchain, Rebecca Campbell, Rahul Seth, Joseph Scharpf, Brian Burkey, Charis Eng
Journal: Cancer Research
Cancer Res (2012) 72 (8_Supplement): 4087.
https://doi.org/10.1158/1538-7445.AM2012-4087
Published: 15 April 2012
View articletitled, Abstract 4087: Microbiomic subprofiles and MDR1 promoter methylation in head and neck squamous cell carcinoma
Journal Articles

Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets

Free
Laura J. Rush, Aparna Raval, Pauline Funchain, Amy J. Johnson, Lisa Smith, David M. Lucas, Melania Bembea, Te-Hui Liu, Nyla A. Heerema, Laura Rassenti, Sandya Liyanarachchi, Ramana Davuluri, John C. Byrd, Christoph Plass
Journal: Cancer Research
Cancer Res (2004) 64 (7): 2424–2433.
https://doi.org/10.1158/0008-5472.CAN-03-2870
Published: 01 April 2004
View articletitled, Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets
Open the PDF for Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets in another window